Picture1.jpg
Curium Anuncia Que PYLCLARI®, un Innovador Trazador PET 18F-PSMA Indicado en Pacientes Con Cáncer De Próstata, Ya Está Disponible en España
10 sept. 2024 04h30 HE | Curium US LLC
PARIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Curium, líder mundial en medicina nuclear, ha anunciado hoy que PYLCLARI ® ya está disponible en España para pacientes con cáncer de próstata. PYLCLARI®...
Picture1.jpg
Curium Announces PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – Is Now Available in Spain
10 sept. 2024 04h30 HE | Curium
CURIUM ANNOUNCES PYLCLARI® – AN INNOVATIVE 18F-PSMA PET TRACER INDICATED IN PATIENTS WITH PROSTATE CANCER – IS NOW AVAILABLE IN SPAIN
Innovation and Growi
Innovation and Growing Demand for Nuclear Medicine Drives Curium Expansion and 10-Year Commitment to St. Louis, MO
02 mars 2023 07h44 HE | Curium
Renaissance in nuclear medicine to attract top St. Louis talentNorth America Headquarters to call Westport Plaza home for the next 10 yearsOver 100 new jobs in the next 3 years ST. LOUIS, March 02,...